Articles tagged with: Istodax
News»
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts' thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology -- which undoubtedly will host discussions of many potential new myeloma treatments -- it seems an appropriate time to go back to the experts' review from …
News»
Results of a small, Phase 1/2 Australian study indicate that a combination of Istodax, Velcade, and dexamethasone may be effective in relapsed and refractory multiple myeloma patients.
According to the study authors, patients who participated in the study achieved durable responses and experienced manageable treatment-related side effects with the Istodax combination treatment.
Based on their findings, the study authors concluded that the Istodax combination treatment warrants further evaluation.
“We continue to examine this combination on a [21-day] schedule. We are also planning a study of Revlimid and [Istodax] in a number of …
News»
The results of a recent Phase 2 clinical trial indicate that the new drug Istodax, administered alone, is unlikely to achieve a significant response rate in therapy-resistant multiple myeloma patients. However, the results indicate that that Istodax may help stabilize M-protein production, resolve high calcium levels, or reduce bone pain in some multiple myeloma patients.
Istodax (romidepsin) is a cyclic peptide that inhibits an enzyme in cancer cells known as histone deacetylase (HDAC). By inhibiting HDAC, Istodax disrupts the cell cycle and causes cancer cell death. Istodax is marketed by Celgene Corporation …
NewsFlash »
Celgene To Acquire Gloucester Pharmaceuticals And Potential Myeloma Drug Istodax – Celgene Corporation has announced its decision to merge with the privately held Gloucester Pharmaceuticals Inc. for $340 million in cash plus $300 million in future payments. The transaction is expected to be completed in early 2010. Gloucester’s first drug, Istodax (romidepsin), received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade (bortezomib) in multiple myeloma are underway. For more information, please see the Celgene press release.
MMRC Honors Dana-Farber Cancer Institute With 2009 Center Of The Year Award – The Multiple Myeloma Research Consortium (MMRC) awarded its 2009 Center of the Year Award to the Dana-Farber Cancer Institute for its excellence in the number of clinical trials launched, the speed at which they were opened, and the number of patients enrolled in the trials. The Award will be accompanied by a one-year grant to fund a multiple myeloma clinical trial project coordinator at Dana-Farber. For more information, please see the MMRC press release.
Volunteer At 2010 Walt Disney World Marathon Weekend – The 2010 Walt Disney World Marathon Weekend will take place January 7 through 10. Events include the Walt Disney World Marathon and Half Marathon, Goofy’s Race and a Half Challenge, Disney/Pixar UP & Away Family Fun Run 5K, Mickey’s Marathon Kids’ Fest and Mickey Mile, and Disney’s Health & Fitness Expo. The Marathon Weekend will benefit the Leukemia & Lymphoma Society. Registration to participate in the events is almost full, but volunteers are still needed to provide assistance during the weekend. For more information, please see the Disney World Sports Web site.
For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.
Resources, Treatments Under Development»
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an enzyme known as histone deacetylase (HDAC). It alters the production of protein from DNA, inhibits the cell cycle, and causes cancer cells to die. Istodax, received FDA approval in November 2009 for …
